Evidence map›Paper›PMID 41333469›Full record

ArticleFrontiers in immunology2025

IL-12 and GM-CSF engineered dendritic cells enhance the enrichment and selection of tumor-reactive T cells for cancer immunotherapy.

Zhen Liu, Haoyun Li, Zhaoya Gao, Ruoqi Cheng, Jiahua Lu, Xuan Che, Jiebin Dong, Zilong Wang, Zejia Cui, Jin Gu and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zhen Liu *Department of Cell Biology and Stem Cell Research Center, School of Basic Medical Sciences, Peking University Health Science Center, Peking University, Beijing, China.
Haoyun Li *Department of Cell Biology and Stem Cell Research Center, School of Basic Medical Sciences, Peking University Health Science Center, Peking University, Beijing, China.
Zhaoya GaoDepartment of Gastrointestinal Surgery, Peking University Shougang Hospital, Beijing, China.
Ruoqi ChengSchool of Life Sciences, Center for Bioinformatics, Center for Statistical Science, Peking University, Beijing, China.
Jiahua LuSchool of Life Sciences, Center for Bioinformatics, Center for Statistical Science, Peking University, Beijing, China.
Xuan CheDepartment of Cell Biology and Stem Cell Research Center, School of Basic Medical Sciences, Peking University Health Science Center, Peking University, Beijing, China.
Jiebin DongDepartment of Cell Biology and Stem Cell Research Center, School of Basic Medical Sciences, Peking University Health Science Center, Peking University, Beijing, China.
Zilong WangDepartment of Gastrointestinal Surgery, Peking University Shougang Hospital, Beijing, China.
Zejia CuiSchool of Life Sciences, Peking University, Beijing, China.
Jin GuDepartment of Gastrointestinal Surgery, Peking University Shougang Hospital, Beijing, China.
Yun BaiDepartment of Cell Biology and Stem Cell Research Center, School of Basic Medical Sciences, Peking University Health Science Center, Peking University, Beijing, China.
Cheng LiSchool of Life Sciences, Center for Bioinformatics, Center for Statistical Science, Peking University, Beijing, China.
Yinan LiuDepartment of Cell Biology and Stem Cell Research Center, School of Basic Medical Sciences, Peking University Health Science Center, Peking University, Beijing, China.
Chengyan WangDepartment of Cell Biology and Stem Cell Research Center, School of Basic Medical Sciences, Peking University Health Science Center, Peking University, Beijing, China.
Hongkui DengDepartment of Cell Biology and Stem Cell Research Center, School of Basic Medical Sciences, Peking University Health Science Center, Peking University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of tumor-reactive T cells in targeted tumor elimination holds significant potential for cancer immunotherapy, such as Tumor-Infiltrating Lymphocyte (TIL) therapy and TCR-T adoptive immunotherapy. Critical aspects of the effective clinical application of these immunotherapies include the enrichment and selection of tumor antigens and their corresponding reactive T cells. However, current

Indexed as

Dendritic CellsGranulocyte-Macrophage Colony-Stimulating FactorImmunotherapy, AdoptiveInterleukin-12NeoplasmsAnimalsAntigens, NeoplasmCell Line, TumorHumansImmunotherapyLymphocyte ActivationLymphocytes, Tumor-InfiltratingMiceMice, Inbred C57BLAntigens, NeoplasmGranulocyte-Macrophage Colony-Stimulating FactorInterleukin-12DCenrichment and selectionGM-CSFIL-12reactive T cells

Identifiers

PMID41333469
PMCPMC12665776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.